Only ponatinib, a multi-kinase inhibitor, which targets potently native BCR-ABL1, BCR-ABL1T315I, and all known single BCR-ABL1 mutants in vitro as well as in vivo is approved for treatment of CML and Ph+ ALL patients with multi-TKI-resistant disease or presence of the T315I mutation [6]⁠⁠. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.